2018 American Transplant Congress
Robotic Assisted Live Donor Kidney Transplantation – Technique and Outcomes
Background: Robotic assisted kidney transplantation (RAKT) is now a feasible minimally invasive option in place of open living donor kidney transplant (OKT). Here, we briefly…2018 American Transplant Congress
Long-Term Outcomes of a Steroid-Free, Belatacept-Based Immunosuppressive Regimen Plus Sirolimus Using Alentuzumab Induction in Renal Transplantation
The toxicities of CNIs and steroids have a negative impact on kidney transplantation. Belatacept is a safe, non-nephrotoxic alternative to CNIs, that may lead to…2018 American Transplant Congress
Novel Vascular Inflow Offers Renal Transplantation to Recipients with Severe Central and Peripheral Vascular Disease
Background: Absence of suitable implant locations for donor renal vessels may be a major problem in patients with significant central and peripheral vascular disease. We…2018 American Transplant Congress
Prolonged-Release Tacrolimus Dosing in De Novo Kidney Transplantation: Randomized, Open-Label, Pilot Study
A multicenter, randomized, open-label, parallel-group, pilot, 52-wk study in Asian countries that assessed renal function, efficacy, and safety of low vs standard-dose prolonged-release tacrolimus (PRT)…2018 American Transplant Congress
Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study
1TRANSFORM Study Group, Livingston; 2Novartis Pharma AG, Basel, Switzerland.
Purpose: Everolimus (EVR)-facilitated calcineurin inhibitor (CNI) reduction regimens help prevent long-term CNI nephrotoxicity in kidney transplant recipients (KTxRs). TRANSFORM (NCT01950819) is the largest study in…2018 American Transplant Congress
Estimated GFR for Living Kidney Donor Evaluation before and after Donor Nephrectomy
BackgroundKidney transplantation from living donors is an important treatment for patients with kidney failure. An accurate evaluation of renal function must be conducted before and…2018 American Transplant Congress
Superior Renal Function with CNI-Free Everolimus over Standard CNI-Based Regimen: 18 Months Data from the Randomized, Multi-Center MANDELA Trial in De Novo Heart Transplant Recipients
1Mandela Study Group, Germany; 2Novartis, Pharma, Germany.
Purpose: The MANDELA study (NCT00862979) was designed to assess the benefit on renal function of either CNI-free or CNI-minimized EVR-based regimen after early conversion of…2018 American Transplant Congress
Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus
AIM: To describe the long-term outcome of liver transplantation (LT) in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo…2018 American Transplant Congress
Efficacy and Safety of Tocilizumab in Treatment of Acute Antibody Mediated Rejection
Antibody mediated rejection continues to be one of the most detrimental complications of kidney transplant. Multiple therapeutic strategies focused on B cell and/or HLA antibody…2018 American Transplant Congress
Side Effect Profile of Everolimus in Liver Transplant Patients
IntroductionUse of calcineurin inhibitors has been the mainstay of antirejection medications after liver transplant (LT). However, renal toxicity from these drugs remains troublesome. By comparison,…
American Transplant Congress abstracts